Chinese Lung Cancer Biotech Lands $200M In Funding
Chinese lung cancer-focused biotechnology company Avistone Pharmaceuticals said Wednesday it raised more than $200 million in funding in a round that included Vivo Capital, Bain Capital and Primavera Capital....To view the full article, register now.
Already a subscriber? Click here to view full article